SAB Biotherapeutics Reports Increased Operating Expenses and Net Loss in Latest 10-Q Filing

SAB Biotherapeutics, Inc. reported significant financial developments in its latest 10-Q filing for the quarter ending March 31, 2026. The company recorded total operating expenses of $19.998 million, a substantial increase from $10.772 million in the same period last year, reflecting a 85% rise. This increase was primarily driven by heightened research and development costs, which surged to $13.398 million from $7.657 million, marking a 75% increase year-over-year. The net loss for the quarter was $18.869 million, compared to a loss of $5.197 million in the prior year, resulting in a basic and diluted loss per share of $0.35, an improvement from a loss of $0.56 per share in the same quarter of 2025.

The company’s cash and cash equivalents increased to $20.520 million as of March 31, 2026, up from $10.503 million at the end of 2025. This increase was bolstered by the successful completion of a public offering in March 2026, which generated approximately $86.4 million in net proceeds. The offering included the sale of 19.325 million shares of common stock and pre-funded warrants, with an additional 2 million shares sold under the underwriters' option. The funds are earmarked for advancing the company's lead product candidate, SAB-142, through its pivotal Phase 2b clinical trial, as well as for general corporate purposes.

Operationally, SAB Biotherapeutics has made strides in its clinical development efforts. The company is focused on its lead candidate, SAB-142, which is aimed at treating autoimmune type 1 diabetes (T1D). The company has initiated its pivotal Phase 2b clinical trial, known as the SAFEGUARD study, with enrollment ongoing across multiple sites in the U.S., Australia, New Zealand, the U.K., and the European Union. The company also formed a new subsidiary in Australia to conduct preclinical and clinical activities, which qualifies for the Australian government’s research and development tax credit program.

As of March 31, 2026, SAB Biotherapeutics had an accumulated deficit of $129.8 million and anticipates continued losses as it progresses with its product development and seeks regulatory approvals. The company expects to require additional capital to fund its operations and may pursue various financing options, including equity or debt financings. The management remains optimistic about the future, citing the potential of SAB-142 and the ongoing clinical trials as key drivers for the company's growth and market position in the biopharmaceutical sector.